The estimated Net Worth of Dashyant Dhanak is at least $4.17 Milione dollars as of 16 February 2023. Mr. Dhanak owns over 3,693 units of Incyte stock worth over $3,595,632 and over the last 6 years he sold INCY stock worth over $578,419. In addition, he makes $0 as Executive Vice President e Chief Scientific Officer at Incyte.
Dashyant has made over 21 trades of the Incyte stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 3,693 units of INCY stock worth $241,596 on 16 February 2023.
The largest trade he's ever made was exercising 3,845 units of Incyte stock on 10 June 2021 worth over $251,540. On average, Dashyant trades about 669 units every 26 days since 2018. As of 16 February 2023 he still owns at least 56,956 units of Incyte stock.
You can see the complete history of Mr. Dhanak stock trades at the bottom of the page.
Dashyant Dhanak is Vice President and Chief Scientific Officer of the company. Prior to joining Incyte, Dr. Dhanak served as Vice President and Head of Discovery Sciences of Janssen Research & Development, LLC, a wholly-owned subsidiary of Johnson & Johnson, a pharmaceutical company, from 2013 until November 2018. Prior to his tenure at Janssen, Dr. Dhanak spent 25 years at GlaxoSmithKline, a pharmaceutical company, in positions of increased responsibility across multiple disease areas, including his last position as Vice President and Head of the Cancer Epigenetics Discovery Performance Unit. Dr. Dhanak received a B.S. in Chemistry from the University of Manchester Institute of Science and Technology and his Ph.D. from the University of London. He completed his postdoctoral research in natural product synthesis at Northwestern University.
Dashyant Dhanak is 58, he's been the Executive Vice President e Chief Scientific Officer of Incyte since 2018. There are 12 older and 12 younger executives at Incyte. The oldest executive at Incyte Corp. is Pamela M. Murphy, 70, who is the VP of Investor Relations & Corp. Communications.
Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... e Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Incyte executives and other stock owners filed with the SEC include: